Alkermes Head of Medical Affairs Highlights the Importance of Patient-Focused Drug Development | News Direct

Alkermes Head of Medical Affairs Highlights the Importance of Patient-Focused Drug Development

News release by Alkermes

facebook icon linkedin icon twitter icon pinterest icon email icon Northampton, MA | April 19, 2022 01:32 PM Eastern Daylight Time

In a recent article for Boston Business Journal , our head of Medical Affairs, Dr. Kanchan Relwani highlights the importance of patient-focused drug development and how we seek to incorporate the patient voice into all we do.

About Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com